ANKRD17 and hepatocellular carcinoma: ANKRD17 is altered in 7% (n = 25) of HCC patient samples (TCGA, n = 360), with a significant 64% of these patients presenting gene mutations such as high mRNA or gene amplification (Figure S1A).